Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Adenocarcinoma of Lung 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × methoxyamine × Thoracic × Clear all
NCT02535325 2022-06-30

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡